Delivery of Small Molecule EF2 Kinase Inhibitor for Breast and Pancreatic Cancer Cells Using Hyaluronic Acid Based Nanogels

Basit Öğe Kaydı
dc.authoridAy, Mehmet / 0000-0002-1095-1614
dc.authoridCömert Önder, Ferah / 0000-0002-4037-1979
dc.authoridŞahiner, Nurettin / 0000-0003-0120-530X
dc.authoridSağbaş Suner, Selin / 0000-0002-3524-0675
dc.contributor.authorCömert Önder, Ferah
dc.contributor.authorSağbaş Suner, Selin
dc.contributor.authorŞahiner, Nurettin
dc.contributor.authorAy, Mehmet
dc.contributor.authorÖzpolat, Bülent
dc.date.accessioned2025-01-27T20:27:38Z
dc.date.available2025-01-27T20:27:38Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose To evalauted natural polymeric biomaterials including hyaluronic acid (HA) and its copolymeric form HA:Suc nanoparticles (NPs) as drug carrier systems for delivery of hydrophobic small molecule kinase EF2-kinase inhibitor in breast and pancreatic cancer cells. Methods In vitro cellular uptake studies of Rhodamine 6G labaled HA:Suc nanoparticles were evaluated by using flow cytometry analysis and fluorescent microscopy in breast (MDA-MB-231 and MDA-MB-436) and pancreatic cancer cells (PANC-1 and MiaPaca-2). Besides, in vitro release study of compound A (an EF2-kinase inhibitor) as a model hydrophobic drug was performed in the cancer cells. Results These biological evaluation studies indicated that HA and HA:Suc NPs provided a highly effective delivery of compound A were into breast and pancreatic cancer cells, leading to significant inhibition of cell proliferation and colony formation of breast and pancreatic cancer cells. Conclusion HA-sucrose NPs incorporating an EF2-Kinase inhibitor demonstrate significant biologic activity in breast and pancreatic cancer cells. This is the first study that shows natural polymeric drug carriers succesfully deliver a hydrofobic cancer drug into cancer cells. Nanoparticles based on HA:Suc are effective in delivering hydrofobic cancer drugs in breast and pancreatic cancers.
dc.description.sponsorshipScientific and Technological Research Council of Turkey [215S008, TUBITAK-BIDEB 2214A]
dc.description.sponsorshipThe authors are grateful to The Scientific and Technological Research Council of Turkey (Project 215S008) for financial support. Ferah Comert Onder would like to thank the Scientific and Technological Research Council of Turkey for scholarships (Project 215S008 and TUBITAK-BIDEB 2214A programme). The authors declare no competing financial interest.
dc.identifier.doi10.1007/s11095-020-2774-5
dc.identifier.issn0724-8741
dc.identifier.issn1573-904X
dc.identifier.issue3
dc.identifier.pmid32133571
dc.identifier.scopus2-s2.0-85081041268
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s11095-020-2774-5
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22740
dc.identifier.volume37
dc.identifier.wosWOS:000518184900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer/Plenum Publishers
dc.relation.ispartofPharmaceutical Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectbreast and pancreatic cancer
dc.subjectelongation factor 2 kinase
dc.subjectkinase inhibitor
dc.subjecthyaluronic acid-sucrose nanoparticles
dc.subjecttargeted therapy
dc.titleDelivery of Small Molecule EF2 Kinase Inhibitor for Breast and Pancreatic Cancer Cells Using Hyaluronic Acid Based Nanogels
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Mehmet Ay_Makale.pdf
Boyut:
3 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Kimya Bölümü Koleksiyonu
Nanobilim ve Teknoloji Araştırma ve Uygulama Merkezi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu